Credit Suisse analyst Vamil Divan says the news that Pfizer (PFE) has received a warning letter at a plant that is involved with the production of Sandoz and Momenta's (MNTA) Glatopa products is a surprising positive for Teva (TEVA), noting that he has viewed Sandoz and Momenta as most likely to have the first generic Copaxone 40mg on the market. The analyst reiterated an Outperform rating on Teva's stock, and raised his price target on the shares to $42 from $41.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."

Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.